Ac Immune Sa (ACIU)

• $3.03

  $3.24

  $3.07
  

  1.3%

  Downside

  Day's Volatility :6.47%

  Upside

  5.24%

  
• $2.20

  $5.14

  $3.07
  

  28.34%

  Downside

  52 Weeks Volatility :57.2%

  Upside

  40.27%

  

Returns

What analysts predicted

Upside of 232.9%

• Bvf Inc

  19.04%

• BlackRock Inc

  2.64%

• Redmile Group, LLC

  1.83%

• Wells Fargo & Co

  1.13%

• Junked Platinum Investment Management Ltd

  0.96%

• Avidity Partners Management LP

  0.83%

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor